A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
Public ClinicalTrials.gov record NCT00445198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.
Study identification
- NCT ID
- NCT00445198
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2007 (Type not available)
- Primary completion
- Dec 2010 (Actual)
- Completion
- Dec 2010 (Actual)
- Last update posted
- Jun 6, 2018
2007 – 2010
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 13605 | Peoria | Arizona | 85381 | — |
| Site Reference ID/Investigator# 5261 | Phoenix | Arizona | 85013 | — |
| Site Reference ID/Investigator# 11942 | Los Angeles | California | 90095-7187 | — |
| Site Reference ID/Investigator# 4718 | Sacramento | California | 95817 | — |
| Site Reference ID/Investigator# 3755 | Aurora | Colorado | 80045-0510 | — |
| Site Reference ID/Investigator# 8324 | Atlanta | Georgia | 30322 | — |
| Site Reference ID/Investigator# 2623 | Chicago | Illinois | 60612 | — |
| Site Reference ID/Investigator# 2625 | Baltimore | Maryland | 21231-1000 | — |
| Site Reference ID/Investigator# 12343 | Bethesda | Maryland | 20892 | — |
| Site Reference ID/Investigator# 11941 | Boston | Massachusetts | 02215 | — |
| Site Reference ID/Investigator# 2626 | Boston | Massachusetts | 02215 | — |
| Site Reference ID/Investigator# 4934 | Charlotte | North Carolina | 28204 | — |
| Site Reference ID/Investigator# 2624 | Nashville | Tennessee | 37203 | — |
| Site Reference ID/Investigator# 6650 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00445198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2018 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00445198 live on ClinicalTrials.gov.